Literature DB >> 15021925

[High dose L-thyroxine in therapy refractory depression. Case analysis and catamnesis as quality control].

H Pfeiffer1, J Scherer, M Albus.   

Abstract

In a depression unit in a state hospital, 28 patients who had failed in six antidepressant strategies were treated with L-thyroxine at an average dose of 350 micro g/die. Outcomes were moderate in 39.3% and very good in 21.5%, corresponding to 21-item HAMD scores of < or =16 and < or =8 and clinical judgement. Of all patients, 39.3% had to stop treatment due to nonresponse or side effects. Follow-up of all responders to treatment was conducted 45.2 weeks after discharge. Those 28.6% patients who had stopped treatment had significantly more readmissions, i.e., 62.5%, vs none in those who continued, whereas subjective clinical ratings did not differ between the two groups. In contrast to the literature not finding serious side effects in 70 mainly bipolar patients, we found cardial arrhythmia in 10.7% of inpatients and 7.1% of follow-up patients that was serious enough to discontinue treatment. In conclusion, systematic investigation of high-dose L-thyroxine treatment in treatment-resistant depression seems promising and necessary.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15021925     DOI: 10.1007/s00115-003-1550-1

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  26 in total

1.  Bone mineral density and L-thyroxine treatment in rapidly cycling bipolar disorder.

Authors:  L Gyulai; J Jaggi; M S Bauer; S Younkin; L Rubin; M Attie; P C Whybrow
Journal:  Biol Psychiatry       Date:  1997-02-15       Impact factor: 13.382

2.  Treatment of refractory depression with high-dose thyroxine.

Authors:  M Bauer; R Hellweg; K J Gräf; A Baumgartner
Journal:  Neuropsychopharmacology       Date:  1998-06       Impact factor: 7.853

3.  Antidepressant-induced rapid cycling: six case reports.

Authors:  G I Hurowitz; M R Liebowitz
Journal:  J Clin Psychopharmacol       Date:  1993-02       Impact factor: 3.153

4.  Subjective response to and tolerability of long-term supraphysiological doses of levothyroxine in refractory mood disorders.

Authors:  M Bauer; S Priebe; A Berghöfer; T Bschor; U Kiesslinger; P C Whybrow
Journal:  J Affect Disord       Date:  2001-04       Impact factor: 4.839

5.  Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study.

Authors:  J V Parle; P Maisonneuve; M C Sheppard; P Boyle; J A Franklyn
Journal:  Lancet       Date:  2001-09-15       Impact factor: 79.321

6.  An open study of triiodothyronine augmentation of tricyclic antidepressants in inpatients with refractory depression.

Authors:  T K Birkenhäger; M Vegt; W A Nolen
Journal:  Pharmacopsychiatry       Date:  1997-01       Impact factor: 5.788

7.  Rapid cycling bipolar affective disorder. II. Treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study.

Authors:  M S Bauer; P C Whybrow
Journal:  Arch Gen Psychiatry       Date:  1990-05

Review 8.  Thyroxine treatment of benign goiter.

Authors:  R Gärtner
Journal:  Acta Med Austriaca       Date:  1994

9.  Potentiation of antidepressant effects by L-triiodothyronine in tricyclic nonresponders.

Authors:  F K Goodwin; A J Prange; R M Post; G Muscettola; M A Lipton
Journal:  Am J Psychiatry       Date:  1982-01       Impact factor: 18.112

10.  T3 augmentation of antidepressant treatment in T4-replaced thyroid patients.

Authors:  R G Cooke; R T Joffe; A J Levitt
Journal:  J Clin Psychiatry       Date:  1992-01       Impact factor: 4.384

View more
  1 in total

Review 1.  Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics.

Authors:  Rafael T de Sousa; Marcus V Zanetti; Andre R Brunoni; Rodrigo Machado-Vieira
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.